Run, don’t walk, to Megan McArdle’s house for a superb analysis of why Canadian prescription drug prices are lower than in the U.S., and the likely consequences for pharmaceutical R&D. I can vouch for the business reality of her argument; when I worked as a tax consultant I had clients that confronted this painful reality.